Henning Drechsler1,2, Colby Ayers3, James Cutrell3, Reuben Arasaratnam3,4, Roger Bedimo3,4. 1. VA North Texas Health Care System, Dallas, TX, USA. Henning.Drechsler@va.gov. 2. UT Southwestern Medical Center School of Medicine, Dallas, TX, USA. Henning.Drechsler@va.gov. 3. VA North Texas Health Care System, Dallas, TX, USA. 4. UT Southwestern Medical Center School of Medicine, Dallas, TX, USA.
Abstract
BACKGROUND: In people living with HIV (PLWH), statins may be disproportionately effective but remain underutilized. A large prospective trial in patients with low to moderate cardiovascular (ASCVD) risk will reveal whether they should be considered in all PLWH. But its effect size may not apply to real-world PLWH with higher ASCVD and mortality risk. Also, the clinical role of non-statin lipid-lowering therapy (LLT) and LLT adherence in this population is unknown. METHODS: Comparative multi-level marginal structural model for all-cause mortality examining four time-updated exposure levels to LLT, antihypertensives, and aspirin in a virtual cohort of older PLWH. Incident coronary, cerebrovascular, and overall ASCVD events, serious infections, and new cancer diagnoses served as explanatory outcomes. RESULTS: In 23,276 HIV-infected US-veterans who were followed for a median of 5.2 years after virologic suppression overall mortality was 33/1000 patient years: > 3 times higher than in the US population. Use of antihypertensives or aspirin was associated with increased mortality. Past LLT use (> 1 year ago) had no effect on mortality. LLT exposure in the past year was associated with a reduced hazard ratio (HR) of death: 0.59, 95% confidence interval (CI) 0.51-0.69, p < 0.0001 for statin containing LLT and 0.71 (CI: 0.54-0.93), p = 0.03 for statin-free LLT. For consistent LLT use (> 11/12 past months) the HR of death was 0.48 (CI: 0.35-0.66) for statin-only LLT, 0.34 (CI: 0.23-0.52) for combination LLT, and 0.27 (CI: 0.15-0.48) for statin-free LLT (p < 0.0001 for all). The ASCVD risk in these patients was reduced in similar fashion. Use of statin containing LLT was also associated with reduced infection and cancer risk. Multiple contrasting subgroup analyses yielded comparable results. Confounding is unlikely to be a major contributor to our findings. CONCLUSIONS: In PLWH, ongoing LLT use may lead to substantially lower mortality, but consistent long-term adherence may be required to reduce ASCVD risk. Consistent non-statin LLT may be highly effective and should be studied prospectively.
BACKGROUND: In people living with HIV (PLWH), statins may be disproportionately effective but remain underutilized. A large prospective trial in patients with low to moderate cardiovascular (ASCVD) risk will reveal whether they should be considered in all PLWH. But its effect size may not apply to real-world PLWH with higher ASCVD and mortality risk. Also, the clinical role of non-statin lipid-lowering therapy (LLT) and LLT adherence in this population is unknown. METHODS: Comparative multi-level marginal structural model for all-cause mortality examining four time-updated exposure levels to LLT, antihypertensives, and aspirin in a virtual cohort of older PLWH. Incident coronary, cerebrovascular, and overall ASCVD events, serious infections, and new cancer diagnoses served as explanatory outcomes. RESULTS: In 23,276 HIV-infected US-veterans who were followed for a median of 5.2 years after virologic suppression overall mortality was 33/1000 patient years: > 3 times higher than in the US population. Use of antihypertensives or aspirin was associated with increased mortality. Past LLT use (> 1 year ago) had no effect on mortality. LLT exposure in the past year was associated with a reduced hazard ratio (HR) of death: 0.59, 95% confidence interval (CI) 0.51-0.69, p < 0.0001 for statin containing LLT and 0.71 (CI: 0.54-0.93), p = 0.03 for statin-free LLT. For consistent LLT use (> 11/12 past months) the HR of death was 0.48 (CI: 0.35-0.66) for statin-only LLT, 0.34 (CI: 0.23-0.52) for combination LLT, and 0.27 (CI: 0.15-0.48) for statin-free LLT (p < 0.0001 for all). The ASCVD risk in these patients was reduced in similar fashion. Use of statin containing LLT was also associated with reduced infection and cancer risk. Multiple contrasting subgroup analyses yielded comparable results. Confounding is unlikely to be a major contributor to our findings. CONCLUSIONS: In PLWH, ongoing LLT use may lead to substantially lower mortality, but consistent long-term adherence may be required to reduce ASCVD risk. Consistent non-statin LLT may be highly effective and should be studied prospectively.
Authors: Giuseppe Di Lorenzo; Guru Sonpavde; Gregory Pond; Giuseppe Lucarelli; Sabrina Rossetti; Gaetano Facchini; Sarah Scagliarini; Giacomo Cartenì; Piera Federico; Bruno Daniele; Franco Morelli; Teresa Bellelli; Matteo Ferro; Sabino De Placido; Carlo Buonerba Journal: Eur Urol Focus Date: 2017-04-08
Authors: Ariela R Orkaby; Jane A Driver; Yuk-Lam Ho; Bing Lu; Lauren Costa; Jacqueline Honerlaw; Ashley Galloway; Jason L Vassy; Daniel E Forman; J Michael Gaziano; David R Gagnon; Peter W F Wilson; Kelly Cho; Luc Djousse Journal: JAMA Date: 2020-07-07 Impact factor: 56.272
Authors: Samarth S Patel; Viviana A Rodriguez; Mohammad B Siddiqui; Masoud Faridnia; Fei-Pi Lin; Anchalia Chandrakumaran; John Laurenzano; Joseph Clinton; Gurukripa N Kowlgi; Danielle Kirkman; Adam P Sima; Erika Liptrap; Chandra Bhati; Mohammad Shadab Siddiqui Journal: Liver Transpl Date: 2019-08-20 Impact factor: 5.799
Authors: Roger J Bedimo; Lesley S Park; Fatima M Shebl; Keith Sigel; Christopher T Rentsch; Kristina Crothers; Maria C Rodriguez-Barradas; Matthew Bidwell Goetz; Adeel A Butt; Sheldon T Brown; Cynthia Gibert; Amy C Justice; Janet P Tate Journal: AIDS Date: 2021-02-02 Impact factor: 4.632
Authors: Philippe Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Marie-France Brégeault; Anthony J Dalby; Rafael Diaz; Jay M Edelberg; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Guillaume Lecorps; Kenneth W Mahaffey; Angèle Moryusef; Petr Ostadal; Alexander Parkhomenko; Robert Pordy; Matthew T Roe; Pierluigi Tricoci; Robert Vogel; Harvey D White; Andreas M Zeiher; Gregory G Schwartz Journal: Circulation Date: 2019-05-23 Impact factor: 29.690